1228 — Canbridge Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- HK$60.33m
- HK$193.69m
- CNY85.10m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -510.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 12.03 | 31.16 | 78.97 | 102.87 | 85.1 | 155.4 | 310.8 | 125.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company. It is focused on research, development and commercialization of transformative therapies for rare disease. It has a drug portfolio, with three approved drugs and a pipeline of eight assets, targeting rare disease indications that have unmet needs. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. Its pipeline includes Hunterase, Livmarli, CAN106, and CAN103. Hunterase is an enzyme replacement therapy for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Livmarli an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter that is under development to treat rare cholestatic liver diseases including Alagille syndrome and progressive familial intrahepatic cholestasis.
Directors
- Qun Xue CHM (52)
- Glenn Hassan CFO (43)
- Yunxiang Zhu VRD (57)
- Yijun Lu GMG (47)
- Qian Ma SEC
- Shing Cheung Wong SEC
- Kan Chen NED (39)
- Derek Di Rocco NED (41)
- Xiao Le NED (32)
- Peng Kuan Chan NID (58)
- James Geraghty NID (67)
- Richard Gregory NID (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 1st, 2017
- Public Since
- December 10th, 2021
- No. of Employees
- 67
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 424,838,320
- Address
- 139 Main Street 1St Floor, CAMBRIDGE, 02142
- Web
- Phone
- +86 1084148018
- Auditors
- Ernst & Young
Upcoming Events for 1228
Similar to 1228
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Canbridge Pharmaceuticals share price?
As of Today at 19:45 UTC, shares in Canbridge Pharmaceuticals are trading at HK$0.14. This share price information is delayed by 15 minutes.
How has the Canbridge Pharmaceuticals share price performed this year?
Shares in Canbridge Pharmaceuticals last closed at HK$0.14 and the price had moved by -67.73% over the past 365 days. In terms of relative price strength the Canbridge Pharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -67.36% over the past year.
What are the analyst and broker recommendations for Canbridge Pharmaceuticals?
The overall consensus recommendation for Canbridge Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Canbridge Pharmaceuticals dividend yield?
Canbridge Pharmaceuticals does not currently pay a dividend.
Does Canbridge Pharmaceuticals pay a dividend?
Canbridge Pharmaceuticals does not currently pay a dividend.
When does Canbridge Pharmaceuticals next pay dividends?
Canbridge Pharmaceuticals does not currently pay a dividend.
How do I buy Canbridge Pharmaceuticals shares?
To buy shares in Canbridge Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Canbridge Pharmaceuticals?
As of the previous close price of HK$0.14, shares in Canbridge Pharmaceuticals had a market capitalisation of HK$60.33m.
Where are Canbridge Pharmaceuticals shares listed?
Here are the trading details for Canbridge Pharmaceuticals:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1228
What kind of share is Canbridge Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Canbridge Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Canbridge Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Canbridge Pharmaceuticals is HK$12.33. That is 8583.4% above the last closing price of HK$0.14.
Analysts covering Canbridge Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.79 for the next financial year.
Find out moreWhat is the trend in the Canbridge Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Canbridge Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -37.57%.
As of the last closing price of HK$0.14, shares in Canbridge Pharmaceuticals were trading -34.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Canbridge Pharmaceuticals PE Ratio?
The Canbridge Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Canbridge Pharmaceuticals?
Canbridge Pharmaceuticals' management team is headed by:
- Qun Xue - CHM
- Glenn Hassan - CFO
- Yunxiang Zhu - VRD
- Yijun Lu - GMG
- Qian Ma - SEC
- Shing Cheung Wong - SEC
- Kan Chen - NED
- Derek Di Rocco - NED
- Xiao Le - NED
- Peng Kuan Chan - NID
- James Geraghty - NID
- Richard Gregory - NID